Abrdn Healthcare Investors is a closed-ended equity mutual fund that focuses on investing in public equity markets within the healthcare sector. Its customers are primarily investors seeking exposure to growth stocks in biotechnology, medical devices, and pharmaceuticals. Revenue is generated through management fees charged on the assets under management, which typically range from 0.5% to 2% annually. The fund's performance is benchmarked against major indices such as the NASDAQ Biotechnology Index and the S&P 500 Index. Factors supporting its endurance include the growing demand for healthcare investments and the expertise of its management team, while market volatility and competition from other funds could limit its performance.
—
Abrdn Healthcare Investors is a closed-ended equity mutual fund that focuses on investing in public equity markets within the healthcare sector. Its customers are primarily investors seeking exposure to growth stocks in biotechnology, medical devices, and pharmaceuticals. Revenue is generated through management fees charged on the assets under management, which typically range from 0.5% to 2% annually. The fund's performance is benchmarked against major indices such as the NASDAQ Biotechnology Index and the S&P 500 Index. Factors supporting its endurance include the growing demand for healthcare investments and the expertise of its management team, while market volatility and competition from other funds could limit its performance.
—
Daily adjusted close
Abrdn Healthcare Investors is a closed-ended equity mutual fund that focuses on investing in public equity markets within the healthcare sector. Its customers are primarily investors seeking exposure to growth stocks in biotechnology, medical devices, and pharmaceuticals. Revenue is generated through management fees charged on the assets under management, which typically range from 0.5% to 2% annually. The fund's performance is benchmarked against major indices such as the NASDAQ Biotechnology Index and the S&P 500 Index. Factors supporting its endurance include the growing demand for healthcare investments and the expertise of its management team, while market volatility and competition from other funds could limit its performance.